Margin status in ductal carcinoma in situ of the breast;Marge d'exérèse des cancers du sein intracanalaire

Bulletin du Cancer

Volumn 95, Issue 12, 2008, Pages 1155-1159

  Vincens, E ^a   Alves, K ^b   Lauratet, B ^a   Cohen, S ^a   Bakenga, J ^a   Trie, A ^a   Lefranc, J P ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CENTRE HOSPITALIER VICTOR DUPOUY   (France)

Author keywords

Ductal carcinoma in situ; Local recurrence; Margin status; Margin width

Indexed keywords

CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; HUMAN; INTRADUCTAL CARCINOMA; MASTECTOMY; MINIMAL RESIDUAL DISEASE; PREDICTION; REVIEW; TREATMENT OUTCOME;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROGNOSIS; RISK ASSESSMENT;

EID: 58149359435     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0759     Document Type: Review

References (27)

1. Van Dongen JA, Holland R, Peterse JL, Fentiman IS, Lagios MD, Millis RR, et al. Ductal carcinoma in situ of the breast; second EORTC consensus meeting. Eur J Cancer 1992 ; 28(2-3) : 626-9.
2. Silverstein MJ, Barth A, Poller DN, Gierson ED, Colburn WJ, Waisman JR, et al. Ten-year results comparing mastectomy to excision and radiotherapy for ductal carcinoma in situ of the breast. Eur J Cancer 1995 ; 9 : 1425-7.
3. Barillot I, Cutuli B, Arnould L. Carcinome canalaire in situ : est-il éthique de considérer le traitement conservateur comme un standatd ? Cancer Radiother 2004(8) : 9-20.
4. Cutuli B, Cohen-Solal-Le Nir C. De Lafontan B, Mignotte H, Fichet V, Fay R, et al. Ductal carcinoma in situ of the breast results of conservative and radical treatments in 71 patients. Eur J Cancer 2001 ; 37 (18) : 2365-72.
5. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast-conservating treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000 ; 355(9203) : 528-33.
6. American College Of Radiology. Practice guideline for the management of ductal carcinoma in situ of the breast. J Am Coll Surg 2007 ; 205 : 145-61.
7. e Journée de la SFSPM, Deauville, novembre 2005.
8. Faverly DR, Burgers L, Bult P, Holland R. Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol 1994 ; 11(3) : 193-8.
9. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diag Pathol 1994 ; 11 : 167-80.
10. Zavagno G, Goldin E, Mencarelli R, Capitanio G, Del Bianco P. Marconato R, et al. Role of resection margins in patients treated with breast conservation surgery. Cancer 2008 ; 112 : 1923-31.
11. Zafrani B, Jacqueline S, Krishna BC, Capitanio G, Del Bianco P. Marconato R, et al. Histological margin assessment for breast ductal carcinoma in situ: precision and implications. Mod Pathol 2004 ; 17 : 81-8.
12. Neuschatz AC, DiPetrillo T, Steinhoff M, Safaii H, Yunes M, Landa M, et al. The value of breast lumpectomy margin assessment as a predictor of residual burden in ductal carcinoma in situ of the breast. Cancer 2002 ; 94 : 1917-24.
13. Cheng L, Al-Kaisi NK, Gordon NH, Liu AY, Gebrail F, Shenk RR. Relationship berween the size and margin status of ductal carcinoma in situ of the breast and residual disease. J Natl Cancer Inst 1997 ; 89(18): 1356-60.
14. Silverstein MJ, Gierson ED, Colburn WJ, Cope LM, Furmanski M, Senofsky GM, et al. Can intraductal breast carcinoma be excised completely by local excision? Clinical and pathologic predictors. Cancer 1994 ; 73(12): 2985-9.
15. Ratanawichitrasin A, Rybicki LA, Steiger E, Grundfest-Broniatowski S, Hermann RE, Crowe JP. Predicting the likelihood of residual disease in women treated for ductal carcinoma in situ. J Am Coll Surg 1999 ; 188(1) : 17-21.
16. Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of prorocol B-17 intraductal carcinoma. Cancer 1999 ; 86 : 429-38.
17. Cutuli B, Cohen-Solal-le Nir C, de Lafontan B, Mignotte H, Fichet V, Fay R, et al. Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. Int J Radiat Oncol Biol Phys 2002 ; 53(4) : 868-79.
18. Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999 ; 340(19) : 1455-61.
19. Solin LJ, Fourquet A, Vicini FA, Haffty B, Taylor M, McCormick B, McNeese M, et al. Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys \2001 ; 50(4) : 991-1002.
20. Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I. Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853: a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006 ; 24(21) : 3381-7.
21. Kerlikowske K, Molinaro A, Cha I, Ljung BM, Ernster VL, Stewart K, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 2003 ; 95(22): 1692-702.
22. Solin LJ, Fourquet A, Vicini FA, Taylor M, Olivotto IA, Haffty B, et al. Long-term outcome after breast conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 2005 ; 103 : 1137-46.
23. Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, et al. A prognostic index for ductal carcinoma in situ of rhe breast. Cancer 1996 ; 77(11) : 2267-74.
24. MacAusland SG, Hepel JT, Chong FK, Waisman JR, Lewinsky BS, Colburn WJ, et al. An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer 2007 ; 110(12): 2648-53.
25. Gilleard O, Goodman A, Cooper M, Davies M, Dunn J, et al. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J Surg Oncol 2008 ; 6 : 61.
26. Denoux Y, Marnay J, Crouet H, Boute V, Delozier T, Vie B, et al. Evaluation of predictive factors, particularly the Van Nuys index, of local recurrence in ductal carcinoma in situ of the breast: study of 166 cases with conservative treatment and review of the literature. Bull Cancer 2001 ; 88(4) : 419-25.
27. Cutuli B, Fourquet A, Luporsi E, Arnould L, Caron Y, Cremoux P, et al. Recommandation pour la pratique clinique : Standards, Options et Recommandations 2004 pour la prise en charge des carcinomes canalaires in situ du sein (rapport abrégé). Bull Cancer 2005 ; 92(2) : 155-68.